Research across Cancer
Related studies from across the Cancer family.
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
New analysis gives hope for early lung cancer patients who cannot have surgery
This post hoc Bayesian reanalysis of the LUSTRE trial evaluated stereotactic radiotherapy versus conventional radiotherapy in medically inop…
A new statistical review suggests a focused radiation approach may better control early lung cancer for patients who cannot undergo surgery.
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back